Crestline Management, L.P.
CIK
1536054
Location
FORT WORTH, TX
Portfolio Value
Micro
$46,267,384
Diversification
Highly concentrated
Filing Date
Global Rank
#6,584
/ 8,232
▲ 53
Top Industry
Biotechnology
96.4%
3Y Alpha vs SPY
-3.5%
Period ended 2 months ago
Filed May 15, 2026 · 30d
25 quarters · since Mar 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+61.5%
SPY
+76.3%
Annualised alpha
-3.5%
Max drawdown
−23.3%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
3 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
91.7%
+4.7 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
8,451
Highly concentrated+778
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 96.4% | $44,622,573 |
| Technology | 3.6% | $1,644,811 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| EGHT | 8X8 Inc /De/ | +270 | 990,850 | $1,644,811 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
3 positions ·
$46,267,384 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Reduced | 2,210,732 | $42,446,054 | 91.74% | |
| SANA |
Sana Biotechnology, Inc.
Healthcare
|
Reduced | 755,736 | $2,176,519 | 4.70% | |
| EGHT |
8X8 Inc /De/
Technology
|
Added | 990,850 | $1,644,811 | 3.56% |